The Prurigo Nodularis market report provides current treatment practices, emerging drugs, Prurigo Nodularis market share of the individual therapies, current and forecasted Prurigo Nodularis market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Prurigo Nodularis treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Some of the key facts of the report1. The total diagnosed Prurigo Nodularis prevalent population in the 7MM was found to be 539,893 in 2017.2. The total diagnosed prevalent patient population of Prurigo Nodularis in the 7MM was around 46.30% of the total cases in the United States in 2017.3. Females are affected more by Prurigo Nodularis as compared to males.
Scope of the report:-
Request for sample pages @ Prurigo Nodularis market report
Prurigo Nodularis treatment is challenging. The current Prurigo Nodularis market can be classified based on the severity of the disease as mild, moderate, and severe. There is a multimodal treatment algorithm consisting of topical and systemic therapies, where topical therapies are used for treating the visible form of the disease. In contrast, systemic therapies are used for symptomatic treatment. The symptomatic therapy aims to reduce itching and complete healing of lesions. A mild form of the disease includes several topical therapies, such as antihistamines, topical corticosteroids, topical immunosuppressants, topical calcineurin inhibitors, emollients, which are recommended as both an essential therapy and general therapeutic measure.
Topical corticosteroid includes Betamethasone 0.1% cream, which reduces itch significantly, in comparison with an antipruritic moisturizing cream, and also results in nodule flattening. Topical calcineurin inhibitors or immunosuppressants represent a relatively long-term treatment option.
On the other hand, for moderate-to-severe forms of the disease, topical corticosteroids (Betamethasone 0.1%), topical Immunosuppressants/Topical calcineurin inhibitors (pimecrolimus and Tacrolimus), systemic immunosuppressants (for moderate-to-severe cases), systemic corticosteroid (triamcinolone acetonide) along with other relevant therapies such as antidepressants (paroxetine, amitriptyline or mirtazapine), gabapentinoids and opioid receptor antagonists are suggested usually.
Immunosuppressants are considered as a therapeutic option for patients with moderate-to-severe Prurigo Nodularis mainly. Several studies have described the application of immunosuppressive agents, such as cyclosporine in the disease, showing remarkable symptom improvement. During immunosuppressant therapy, it is essential to monitor blood pressure and laboratory values, especially those of the kidneys. Thalidomide and its analogue Lenalidomide are other immunomodulatory drugs that have successfully been used to treat refractory cases of Prurigo Nodularis.
The launch of the emerging therapies is expected to significantly impact Prurigo Nodularis treatment scenario in the upcoming years:-
Prurigo Nodularis Drugs1. Serlopitant2. Nalbuphine ER3. Nemolizumab (CD14152)4. Apremilast (CC-10004)5. M 1181036. KPL-7167. Dupixent (Dupilumab/SAR231893)And many others
The key players in Prurigo Nodularis market are:
1. Menlo Therapeutics2. Trevi Therapeutics3. Galderma4. Amgen5. Maruho6. Kiniksa Pharmaceuticals7. Sanofi8. Regeneron PharmaceuticalsAnd many others
Table of contents1 Key Insights2 Prurigo Nodularis Patient Overview at a Glance3 Executive Summary4 SWOT Analysis5 Disease Background and Overview of Prurigo Nodularis6 Recognized Establishments7 Prurigo Nodularis Epidemiology and Patient Population8 Country-wise Epidemiology of Prurigo nodularis8.1 United States8.2 EU5 Countries8.3 Germany8.4 France8.5 Italy8.6 Spain8.7 United Kingdom8.8 Japan9 Prurigo Nodularis Treatment10 European Guidelines on Prurigo Nodularis11 FDA Recommendations for Prurigo Nodularis Treatment12 Unmet Need13 Prurigo Nodularis Emerging Drugs13.1 Key Competitors13.2 Serlopitant: Menlo Therapeutics13.3 Nalbuphine ER: Trevi Therapeutics13.4 Nemolizumab (CD14152): Galderma13.5 Apremilast (CC-10004): Amgen13.6 M 118103: Maruho13.7 KPL-716: Kiniksa Pharmaceuticals13.8 Dupixent (Dupilumab/SAR231893): Sanofi/Regeneron Pharmaceuticals14 Prurigo Nodularis Market Size15 Attribute Analysis16 Conjoint Analysis17 7MM Prurigo Nodularis Market Outlook17.1 United States18 EU5 Countries18.1 Germany18.2 France18.3 Italy18.4 Spain18.5 United Kingdom19 Japan20 Case Reports21 Market Drivers22 Market Barriers23 Appendix24 Prurigo Nodularis Report Methodology25 DelveInsight Capabilities26 Disclaimer27 About DelveInsight
Media ContactCompany Name: DelveInsightContact Person: Priya MauryaEmail: Send EmailPhone: +919650213330Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/